Exhibit 99.1 BA3011 Supplemental NSCLC and Sarcoma Data 10/2022 1
AXL BA3011-002 (Phase 2 Part 1) - Disposition as of October 2022 24 patients enrolled 6 patients on-going with 0 scan (3 combo) Preliminary Data 2 patients not dosed yet 2 withdrawal of consent early, before the first scan 14 efficacy-evaluable patients* ORR: 5/14 (36%) 12 Non-Sq patients 2 Sq patients ORR: 5/12 (42%) ORR: 0/2 (0%) ORR: 4/8 (50%) ORR: 1/4 (25%) 8 monotherapy 1 Combo 1 Mono 4 combo SD PD 1 CR 4 PRs 2 SD 2 SD 2 PD 1 PD *Average prior lines of therapy = 3 All patients were PD-1 failure with the exception of 1 NSQ patient who failed EGFR treatment Interim data- Data cut-off of Oct 28, 2022 2 confidential
Phase 2 part 1 BA3011 NSCLC – response rate 60 57% 50% # Patients 50 42% Enrolled 24 40 36% Dosed / 0 scan 6 (3 combo) 30 Not yet dosed 2 25% W/D consent 2 20 Efficacy evaluable 14 10 0/2 5/14 5/12 4*/7 4*/8 1**/4 0 NSQ+SQ All NSQ NSQ NSQ NSQ BA3011 + SQ monotherapy monotherapy nivolumab PD-1 Failure W/D – withdrew; NSQ – non-squamous; SQ – squamous Responses include 4 partial responses (*) and one complete response (**) Interim data- Data cut-off of Oct 28, 2022 3 ORR (%)
BA3011: Best Response in Phase 2 Non-Squamous Patients Non-Squamous patients - Phase 2 only 1.8mg/kg Q2W 100 Preliminary Data 80 60 40 PD PD SD PD SD SD SD PR* PR PR CR PR* EGFR Failure 20 0 -20 -40 -60 ---Monotherapy ---Combination -80 nd *2 scan pending TmPS range 1% - 100% -100 Average prior lines of therapy = 3 All patients were PD-1 failure with the exception of 1 NSQ patient who failed EGFR treatment Interim data- Data cut-off of Oct 28, 2022 4 confidential %Change in Sum of Target Lesions
BA3011 NSCLC: Safety and tolerability profile Phase 2 at the RP2D 1.8 mg/kg Q2W BA3011 + Opdivo Characteristic BA3011 (N=13) (N=9) Any Adverse Events (AEs) 11 (85%) 6 (67%) 1 Related AEs with CTCAE Grade 3 or 4 (31%) 2 (22%) ▪ No treatment-related deaths 2 4 2 Any related serious AEs 2 (15%)* 2 (22%)^ ▪ Few treatment-related SAEs 2 Related AEs leading to death 0 0 ▪ Few AEs leading to treatment discontinuation Related AEs leading to treatment § 1 (8%) 0 2 discontinuation ▪ No clinically meaningful on-target toxicity Grade 1-2 (9%) observed over background Constipation Grade 3-4 (0%) ▪ Differentiated profile due to avoiding on-target off-tumor toxicity All Grade 1-2 (4.5%) Peripheral Neuropathy Grade 3-4 (0%) Grade 1-2 (14%) Diarrhea Grade 3-4 (0%) Low-grade constipation observed is consistent with baseline levels seen in advanced cancer patients Company material – confidential Interim data- Data cut-off of Oct 25, 2022 1 Note: CTCAE: Common Terminology Criteria for Adverse Events. The NCI Common Terminology Criteria for Adverse Events is a descriptive terminology which is utilized for Adverse Event (AE) 2 reporting. A grading (severity) scale is provided for each AE term. As assessed by the investigator. Missing responses are counted as related. *Hyperglycemia & infusion reaction ^creatinine § increase & Acute kidney injury; Infusion reaction 5
Phase 2 Part 1 Topline Interim Analysis Results following BA3011 in refractory sarcoma subtypes Advance Phase 2 Part 1 Interim Results P2 Part 2 Leiomyosarcoma Leiomyosarcoma; Evaluating (n=18)* PFS rate 12W 32% STS Synovial sarcoma Synovial Go – Label Pendi (n=5)* PFS rate 12W 54% Expansion ng Liposarcoma Liposarcoma Go – Label BA3011 Monotherapy (n=6)* PFS rate 12W 67% Expansion Interim results satisfied pre- (n=105) defined ‘Go’ criteria into part 2 of Other Soft Tissue / UPS UPS Go – Initial § (n=19 / 8 )* PR = 2 / 6 Indication the Phase 2 BA3011 study in multiple sarcoma subtypes: Go – Label Osteosarcoma Osteosarcoma; Bone • UPS – clear guidance from Expansion (n=6)* PFS rate 12W 67% FDA, moving in phase 2, part 2 Ewing sarcoma Ewing sarcoma as initial indication (n=4)* Pending • Osteosarcoma, liposarcoma Others (chondro/chordo) Others (chondro/chordo) and synovial – pursue Pending (n=11 [6/ 3])* registration post UPS approval Combination with PD-1 CD20 Combo w/ PD-1; PR = 1 / 1 (UPS)** & CD 20 Positive Evaluating (n=20) (BA3011 + Opdivo) PFS rate 12W (combo overall) 32% (n=14)* CD 20 Negative Combo w/ PD-1, 1 PR (LMS); Evaluating (n=12)* PFS rate 12W 31% Cohorts in gray – continue to interim read-out Pre-defined criteria for each subgroup up to 10 patients: ‘No Go’ if 0 CR/PR and PFS rate at 3 months <40%; ‘Go’ if ≥1 CR/PR or PFS rate at 3 months ≥40%. * As of data cut-off Oct 17, 2022; Cohorts in gray continuing enrollment until sufficient sample size is achieved. **Included in UPS cohort. BA3011 dose 1.8 mg/kg Q2W. PFS, progression-free survival; PR, partial response; UPS, § undifferentiated pleomorphic sarcoma. Of 8 enrolled, 6 efficacy evaluable; 2 on-going with 1 scan. 6
Undifferentiated Pleomorphic Sarcoma (UPS): Phase 1 & 2 (1.8mg/kg; n=10) BioAtla Page 1 of 1 Protocol: BA3011-001 Figure 1.3.2.1.1 Progression-free Survival per Investigator Assessment for UPS Patients with TmPS or TcPS >= 70 in Change Target Lesion From Baseline (%) Progression-free Survival Phase 1&2 1.0 Events Median(mos) PFS 12WK Events Median (mos) PFS 3mo n(%) (95% CI) %(95% CI) All Patients 7 ( 70.0) 6.8 (1.4-NE) 50.0 (18.4, 75.3) 100 n(%) (95% CI) % (95%CI) 0.8 80 All 7(70.0) 6.8 (1.4 – NE) 50.0 (18.4, 75.3) 60 Patients 40 0.6 20 0 c c 0.4 -20 Combo -40 0.2 -60 -80 0.0 -100 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Number at Risk Months from First Dose Months from First Dose 10 10 8 4 4 4 4 3 3 3 3 2 2 2 2 1 1 1 1 1 1 1 1 0 All Patients Number at Risk Program name: FPFS_UPS.sas, Data Extraction Date: 17OCT2022, Run date: 20OCT2022 All Patients 10 10 8 4 4 4 4 3 3 3 3 2 2 2 2 1 1 1 1 1 1 1 1 0 ▪ Combined Phase 1 & 2: enrolled = 10; efficacy evaluable = 8; on-going with 1 scan = 2 ― 4 / 8 patients achieved PRs, with an ORR of 50% and PFS rate at 3 months of 50% ― Responses to BA3011 treatment are durable, with partial responders remaining on treatment for extended periods of time ▪ Interim results satisfied the pre-defined Go criteria of UPS cohort into part 2 of the Phase 2 study Interim data- Data cut-off of Oct 17, 2022 7 Progress-Free Survival Probability
Osteosarcoma: Phase 2 Change in Target Lesion and Progression Free Survival (1.8mg/kg; n=6) BioAtla Page 1 of 1 Protocol: BA3011-001 Figure 1.3.1.9.1 Progression-free Survival per Investigator Assessment for Patients with BA3011 alone & in Combination with Nivolumab - Bone(Osterosarcoma) in Phase 2 1.0 Events Median(mos) PFS 12WK Events Median (mos) PFS 3mo n(%) (95% CI) %(95% CI) All Patients 6 (100.0) 4.2 (1.2-NE) 66.7 (19.5, 90.4) n(%) (95% CI) % (95%CI) 0.8 6(100.0) 4.2 (1.2 – NE) All Patients 66.7 (19.5, 90.4) 0.6 c 0.4 0.2 0.0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 Number at Risk Months from First Dose 6 6 4 4 3 2 1 1 1 1 1 1 0 All Patients Program name: FPFS_OSTERO.sas, Data Extraction Date: 17OCT2022, Run date: 19OCT2022 ▪ Of 6 patients enrolled, PFS rate at 3 months was 66.7% ▪ Interim results satisfied the pre-defined Go criteria of osteosarcoma cohort into part 2 of the Phase 2 study Interim data- Data cut-off of Oct 17, 2022 Recent independent phase 2 study demonstrated placebo PFS rate at 2 months for 1st and 2nd line metastatic osteosarcoma of ~0% (www.thelancet.com/oncology Vol 20 January 2019) 8 Progress-Free Survival Probability Progression Free Survival Probability
Liposarcoma and Synovial sarcoma Phase 2 Progression Free Survival Synovial Sarcoma BioAtla Page 1 of 1 Liposarcoma Change Target Lesion From Baseline (%) Protocol: BA3011-001 BioAtla Page 1 of 1 BA3011 1.8mg/kg Q2W BA3011 1.8mg/kg Q2W Figure 1.3.1.6.1 Progression -Free Survival by AXL for Patients with BA3011 alone - STS (Synovial) Protocol: BA3011-001 Figure 1.3.1.5.2 Progression-free Survival per Investigator Assessment for STS Patients with BA3011 alone & in As-treated Sarc n=5 oma Subjects in Phase 2 n=6 Combination with Nivolumab - STS(Liposarcomas) in Phase 2 1.0 Events Median(mos) PFS 12WK Events Median (mos) PFS 3mo 1.0 Events Median(mos) PFS 12WK n(%) (95% CI) %(95% CI) Events Median (mos) PFS 3mo n(%) TmPS or(9 TcP 5 S% >= C 70 I ) 3( 60.0) 3.5(1.1-4.7) % 50( .09 (55 ..8%C , 84.5I) ) n(%) (95% CI) %(95% CI) All Patients 4 ( 66.7) 4.6 (0.2-NE) 66.7 (19.5, 90.4) TmPS ≥ 70 n(%) (95% CI) % (95%CI) 4(80.0) 4.4 (1.1 – NE) TmPS>=70 53.3 (6.8, 86.3) 0.8 4 (66.7) 4.6 (0.2 – NE) 0.8 TmPS>=70 66.7 (19.5, 90.4) 0.6 0.6 c c 0.4 0.4 0.2 0.2 0.0 0.0 Months from First Dose 0 1 2 3 4 5 6 0 1 2 3 4 5 6 7 8 Number at Risk Months from First Dose Number at Risk 5 4 3 1 1 0 Months from First Dose TmPS or TcPS >= 70 BA3011 All Patients 6 5 4 3 3 1 1 0 Program name: fpfs_13161.sas, Data Extraction Date: 25Jul2022, Run date: 07AUG2022 Program name: FPFS_LIPO.sas, Data Extraction Date: 17OCT2022, Run date: 19OCT2022 ▪ Interim results satisfied the pre-defined Go criteria of liposarcoma and synovial sarcoma cohorts into part 2 of the Phase 2 study. Interim data- Data cut-off of Oct 17, 2022 9 Progress-Free Survival Probability Progress-Free Survival Probability
BA3011 Sarcoma: Safety and Tolerability Profile Phase 2 at the RP2D 1.8 mg/kg Q2W Overview Mecbo– BA3011 ▪ AEs consistent with MMAE-based toxicity, including: o Reversible myelosuppression Grade 1-2 (19%) o Transient liver enzyme elevation Constipation Grade 3-4 (1%) o Metabolic disturbances ▪ Few related SAEs Peripheral Neuropathy All Grade 1-2 (19%) ▪ Few related AEs leading to treatment discontinuation Grade 1-2 (19%) Diarrhea Grade 3-4 (0%) CAB AXL-ADC Mecbo– BA3011 Dosing 1.8mg/kg Q2W Constipation is believed to be an on-target mediated effect (safety population Phase 2) Low-grade constipation observed is consistent with baseline levels seen in advanced cancer patients BA3011 + Nivo BA3011 Characteristic (N=63) (n=26) 60 ( 95%) 24 (92%) Any Adverse Events (AEs)• No clinically meaningful on-target toxicity observed • Differentiated profile due to advantageous 1 Related AEs with CTCAE Grade 17 ( 27%) 8 (30%) pharmacokinetic characteristics of CAB ADCs 2 3 or 4 2 Any related serious AEs 5 ( 8%) 4 (15%) 2 0 0 Related AEs leading to death Related AEs leading to § ^ 3 (5%) 1 (3.8%) 2 treatment discontinuation Note: 1CTCAE: Common Terminology Criteria for Adverse Events. The NCI Common Terminology Criteria for Adverse Events is a descriptive terminology which is utilized for Adverse Event (AE) reporting. A grading (severity) scale is provided for each AE term. 2As assessed by the § investigator. Missing responses are counted as related. Grade 2 peripheral neuropathy; pancreatitis; ^grade 2 Ileus Data cut-off of Oct 17 2022 10
UPS – Part 2 of the Phase 2 study (potentially registrational) • Written feedback received from the FDA to the proposed part 2 of the Phase 2 study design, including selection of primary endpoint (ORR) and size of the study (n=80) • FDA supportive of including a more intensive dosing arm • Protocol being finalized post FDA written feedback • Anticipate study enrollment commencement by year-end 11